Back to Trials
NCT07413666PHASE1RecruitingAccepts Healthy Volunteers

A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years

Centessa Pharmaceuticals (UK) Limited

Start Date

2/25/2026

Completion Date

6/30/2027

Summary

Characterize the safety, tolerability and pharmacokinetics of ORX489 following single and multiple doses.

Eligibility Criteria

Age Range: 18 years to 60 years

Inclusion Criteria: * Healthy males or females as determined by assessments at the Screening Visit. * For Parts A, B, C, and D: Participants must be at least 18 years of age and no more than 60 years of age at the Screening Exclusion Criteria: * Presence of significant cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological, or psychiatric disease, as determined by medical history, physical examination, and screening investigations. * History of seizure disorder, any other condition that increases the risk of seizure * Has a clinically significant sleep disorder, including insomnia or sleep apnea

Interventions

DRUG

ORX489 Tablets

OTHER

Placebo Tablets

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Healthy Adult Male and Female Volunteers

Locations

Celerion

Lincoln, Nebraska 68502

United States